

**INTENDED USE**

The Parvovirus Antibody Test Kit is used for the detection of Parvovirus IgG antibody in canine plasma and serum.

ANALYTICAL PRINCIPLE

Parvovirus IgG-specific antibody in diluted samples is allowed to bind to microwell-bound Parvovirus antigen. After washing unbound materials, HRP-conjugate is allowed to bind to the Parvovirus IgG antibody-antigen complex. Unbound HRP-conjugate is washed away and TMB is allowed to react with bound HRP-conjugate. The reaction is stopped and the microwell is read. The intensity of the color produced in the HRP-TMB reaction is proportional to the amount of IgG-specific antibody in the sample.

SPECIMEN REQUIREMENTS

Serum and plasma samples are acceptable. Avoid repetitive freezing and thawing of samples.

REAGENTS**Precautions & Safety Notes**

•WEAR LATEX GLOVES, FACE SHIELDS AND A LAB COAT WHEN HANDLING SPECIMENS AND OTHER HAZARDOUS REAGENTS

•FOR *IN VITRO* USE, POTENTIAL BIOHAZARDOUS MATERIAL. HANDLE ASSAY REAGENTS AS IF CAPABLE OF TRANSMITTING AN INFECTIOUS AGENT.

•The Sample Diluent, Positive Control, Negative Control, and Wash Buffer contain 0.05% ProClin 300. Avoid contact of these reagents with skin or eyes.

Kit Components

ID	Reagent	Part Number	Quantity
	Parvovirus Antibody Test Kit	CPV-1000	96 Test
SD	Sample Diluent [Contains: PBS, BSA, 0.05% ProClin 300]	SDFEA-1001	35 ml
A	Negative Control [Contains: Canine Serum Negative for Parvovirus IgG, 0.05% ProClin 300] See QC Certificate for value	CPV - 1001	70 µl
B	Positive Control [Contains: Canine Serum Positive for Parvovirus IgG, 0.05% ProClin 300] See QC Certificate for value	CPV - 1002	70 µl
C	Microwell Plate [Contains: Parvovirus Antigen]	CPV - 1003	96 Well Plate
D	HRP Conjugate [Contains: HRP Conjugate]	CPV - 1004	10 ml
WB	20X Wash Buffer Concentrate [Contains: Tris Buffer, 0.01% Tween-20, NaCl, 0.05% ProClin 300]	WBFEA-1001	50 ml
TS	TMB Solution [Contains TMB] Keep away from light	TMBS-1001	10 ml
SS	Stop Solution [Contains: 1N Sulfuric Acid]	SSFEA-1001	10 ml

MATERIALS

The following materials are needed but not supplied.

- Variable Pipettors and Tips
- Stir Bar & Stirrer
- 12x75 mm disposable borosilicate glass culture tubes
- Test Tube Rack, polypropylene
- Vortexer
- Microwell Plate Film Sealer
- ELISA Plate Washer
- ELISA Plate Reader
- Refrigerator (for kit storage)

PROCEDURE PRECAUTIONS

- Bring reagents to room temperature before use.
- Use clean instruments & equipments.
- Unused microwells should be sealed tightly using laboratory tape in the foil pouch until further use.
- Handle microwells with care.
- Minimize air bubbles in microwells.
- Microwells should not contain liquid after the washing steps. To ensure that liquids are removed from microwells after washing steps, microwells can be tapped against clean paper towels.

REAGENT PREPARATION**1X Wash Buffer Preparation**

1. Add 1 unit of volume of 20X Wash Buffer Concentrate (**WB**) to 19 units of volume of DI water. For example, add **50 ml** 20X Wash Buffer Concentrate (**WB**) to **950 ml** of DI water.
2. Mix the Wash Buffer Preparation well.

PROCEDURE

1. Dilute controls (**A**, **B**) and samples **1:25** by adding **10 µl** of sample to **240 µl** of Sample Diluent (**SD**) in a glass tube.
2. Vortex the tubes.
3. Dilute samples for a final dilution of **1:100** by adding **40 µl** of the **1:25 diluted samples** from step 1 to **120 µl** of Sample Diluent (**SD**) into a separate glass tube.
4. Vortex the tubes.
5. Dispense **100 µl** of **diluted Negative Control, Positive Control**, and the **diluted samples** into designated wells of the Microwell Plate (**C**). The 1:25 and 1:100 dilutions of samples should both be assayed – each being dispensed into separate wells.
6. Cover the wells.
7. Incubate the wells for **30 minutes** at **room temperature**.
8. Wash each well **3 times** with **300 µl** of **1X Wash Buffer Preparation**.
9. Dispense **100 µl** of HRP Conjugate (**D**) to each well.
10. Cover the wells.
11. Incubate the wells for **30 minutes** at **room temperature**.
12. Wash each well **3 times** with **300 µl** of **1X Wash Buffer Preparation**.
13. Dispense **100 µl** of TMB Solution (**TS**) to each well.
14. Cover the wells.
15. Incubate the wells for **15 minutes** at **room temperature** and **protect from light**.
16. Dispense **100 µl** of Stop Solution (**SS**) to each well.
17. Read the wells in a microwell reader at **450 nm**.



PROCEDURAL NOTES

•Evaluation of samples should be based on the Sample to Negative Ratio.

EXPECTED VALUES

A total of 93 dogs were evaluated for the Parvovirus antibody using IVD Technologies' Parvovirus Antibody Test Kit and an immunofluorescence assay. Twenty-four (24) dogs were evaluated before and three months after they received a Parvovirus vaccination. The optical density (OD) before vaccination was 0.144 – 0.432. After vaccination, the OD was 0.500 – >3. Sixty-nine (69) dogs were evaluated at least three months after receiving a Parvovirus vaccination. The OD for these dogs was 0.362 – >3. The sample to negative (SN) ratios were based on these data.

Sample to Negative Ratio Calculation

Sample to Negative Ratio

= O.D. Sample / O.D. Negative Control

- The Sample to Negative Ratio is equal to the O.D. of the Sample divided by the O.D. of the Negative Control.

Sample to Negative Ratio Interpretation

At 1:25 if the Sample to Negative Ratio (S/N Ratio) is > 1 then the patient is positive for Parvovirus antibody. If the S/N Ratio is < 1 then the patient is negative for Parvovirus antibody.

At 1:100 if the S/N Ratio is > 1 then the patient has protective immunity. If the S/N Ratio is < 1 then the patient has low immunity.

Sample to Negative Ratio Table

S/N Ratio at 1:25 dilution	
< 1.0	Negative
> 1.0	Positive
S/N Ratio at 1:100 dilution	
< 1.0	Low Immunity
> 1.0	Protective Immunity

REFERENCES

Brunner CJ, Swango LJ (1985). Canine parvovirus infection. Effect on the immune system and factors that predispose to severe disease. *Comp. contin. Educ. Vet. Prac.* 12: 979–988.

Buonavoglia C, Tollis M, Buonavoglia D, Puccini A (1992). Response of pups with material derived antibody to modified-live canine parvovirus vaccines. *Comp. Immunol. Microbiol. Infect. Dis.* 15: 281–283.

D,Chu Hsien-Jue (2004). Three-Year Duration of Immunity for Canine Distemper, Adenovirus, and Parvovirus after Vaccination with a Multivalent Canine Vaccine. *Intl. J Appl. Res Vet Med* 2(4): 227–234

Naveh A, Waner T, Wudovsky II, Zekaria D, Harrus S, Freeman E, Fuchs P, Olshevsky, U (1995). A rapid self – contained immunoblot ELISA test kit for the evaluation of antibody to canine parvovirus in dogs. *Proceedings of 3rd international congress of veterinary virology, Interlaken Switzerland, 1994*, pp. 218–221.

Pollock RVH, Carmichael LE (1982). Maternally derived immunity to Canine Parvovirus infection: Transfer, decline and Interference with vaccination. *J. Am. Vet. Med. Assoc.* 180: 37–42.

Truyen U (2001). Canine parvovirus. In: *Recent Advances in canine infectious diseases*, Carmichael LE (ed), International Veterinary Information Service, U. S. A.

Twark L Dodds WJ (2000). Clinical use of serum parvovirus and distemper virus antibody titers for determining revaccination strategies in healthy dogs. *J. Am Vet Assoc.* 7: 217(1): 1021–1024.

Waner T, Naveh A, Wudovsky T, Carmichael LE (1996). Assessment of maternal antibody decay and response to canine parvovirus vaccination using an enzyme – linked immunosorbent assay. *J. Vet. Diagn. Invest.* 8: 427–432.

Waner T (2002). Response of puppies to vaccination to canine distemper virus and canine parvovirus. *27th WSAVA Congress, Granada, Spain.*

Waner T (2003). Evaluation of a rapid dot – ELISA kit for canine parvovirus and canine distemper virus Immunoglobulin M(IgM) and G(IgG) antibodies. *The veterinary record* (in press).

Waner T (2004). A Review of Current International Vaccination Trends for Dogs and Cats. Are We Up To Date and. In-Line with Contemporary Thinking? *J. Israel. Vet. Med. Assoc* 59 (3)

Waner T, Keren-kornblatt E, Shemesh O, Mazar S (2004). Diagnosis of acute canine parvovirus infection (CPV) in naturally infected Dogs using IgM and IgG rapid dot Elisa. *J. Israel. Vet. Med. Assoc.* 59(1-2): 12-15.

Waner T, Mazar S, Keren-Kornblatt E (2006). Application of a Dot Enzyme-Linked Immunosorbent Assay for Evaluation of the Immune Status to Canine Parvovirus and Distemper virus in Adult Dogs Before Revaccination. *J. Vet Diagn Invest* 18(3): 267–270.

Manufacturer Made in the USA
IVD Technologies 2002 S. Grand Avenue, Suite A Santa Ana, CA 92705 USA Tel: 1(714)549-5050 Fax: 1(714)549-5055 info@ivdtechnologies.com www.ivdtechnologies.com